Colorectal Cancer Clinical Trials & Research at St. Joseph Health Medical Group
Colorectal cancer is the third most common type of cancer in men and women
in the U.S. Most colorectal cancers are adenocarcinomas (cancers that
begin in cells that make and release mucus and other fluids). Colorectal
cancer often begins as a growth called a polyp, which may form on the
inner wall of the colon or rectum. Some polyps become cancer over time.
Finding and removing polyps can prevent colorectal cancer.
St. Joseph Health Medical Group is currently enrolling patients for the
following colorectal cancer clinical trials:
Gastric Cancer
Colorectal Cancer
Gastric
A Phase 3, Double-blind, Randomized Study of BGB-290 versus Placebo as
Maintenance Therapy in Patients with Inoperable Locally Advanced or Metastatic
Gastric Cancer that Responded to Platinum-based First-line Chemotherapy (BeiGene)
Phase III
The purpose of this study is to compare the efficacy and safety of single
agent poly (ADP-ribose) polymerase (PARP) inhibitor BGB-290 to placebo
as maintenance therapy in subjects with advanced or inoperable gastric
cancer who have responded to first line platinum based chemotherapy. Subjects
are randomized 1:1 to BGB-290 (Arm A) or placebo (Arm B). Patients must
have achieved a partial response that is maintained for ≥ 4 weeks or
a complete response with platinum-based first-line chemotherapy.
Treatment agent: BGB-290 (PARPi)
PI:
Thomas Stanton, MD
Study Coordinator: Sabine Ucik //
Sabine.Ucik@stjoe.org // (707) 521-3830
Resources and Links:
clinicaltrials.gov NCT No: NCT03427814
Colorectal
A Phase III Study of BBI-608 in Combination With 5-Fluorouracil, Leucovorin,
Irinotecan (FOLFIRI) in Adult Patients With Previously Treated Metastatic
Colorectal Cancer (CanStem)
Phase III
This is an international multi-center, prospective, open-label trial of
the cancer stem cell pathway inhibitor napabucasin plus standard bi-weekly
FOLFIRI versus standard bi-weekly FOLFIRI in adult patients with metastatic
colorectal cancer following progression on first-line FOLFOX or XELOX
with or without bevacizumab.
Treatment agent: Napabucasin
PI:
Ian Anderson, MD
Study Coordinator: Sabine Ucik //
Sabine.Ucik@stjoe.org // (707) 521-3830
Resources and Links:
clinicaltrials.gov NCT No: NCT02753127